Shares in Moderna have been under pressure after the company posted a third-quarter loss of $3.6 billion and a steep fall in COVID-19 vaccine sales, although it still thin
The UK's Joint Committee on Vaccinations and Immunisations (JCVI) has said that Moderna's bivalent COVID-19 vaccine should be used for the autumn booster campaign in adults.
BioNTech has responded to a patent infringement lawsuit filed by fellow German biotech CureVac over its COVID-19 vaccine, saying it will "vigorously" defend itself.
Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.
Moderna has reported preliminary clinical results with a bivalent version of its COVID-19 vaccine that combines its original version with another targeting the Beta variant, and seems to of
It is too early to consider widespread use of a second COVID-19 vaccine booster dose, according to the European Centre for Disease Prevention and Control (ECDC) and EMA's COVID-19 task forc
In another example of the pharma industry embracing generative artificial intelligence (genAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio